BioVie
Pre-clinicalBioVie believes that inflammation is central to the development and progression of Alzheimer’s disease. BioVie’s different approach focuses on our novel molecule, bezisterim, currently being studied in people diagnosed with Alzheimer’s disease, and the hypotheses that selective modulation of inflammation, and the enhancement of energy transfer (insulin sensitivity) in the brain, may be able to improve memory and thinking, and may protect against neurodegeneration.
About
BioVie believes that inflammation is central to the development and progression of Alzheimer’s disease. BioVie’s different approach focuses on our novel molecule, bezisterim, currently being studied in people diagnosed with Alzheimer’s disease, and the hypotheses that selective modulation of inflammation, and the enhancement of energy transfer (insulin sensitivity) in the brain, may be able to improve memory and thinking, and may protect against neurodegeneration.
Company Info
Contact
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile